Cozzarini, C. [23] |
Prospective phase I-II for adjuvant RT |
Milan, Italy |
247 patients |
65.8Gy/2.35Gy/28 fractions adj. RT for 117 pat.; 71.4-72.8Gy/2.55Gy/28 fractions salvage RT for 80 pat.; 58Gy/2.9Gy/20 fractions for 50 pat. Conventional arm 929 pat. 70.2Gy/1.8Gy/39 fractions |
72.6Gy adjuvant RT; 83.0Gy salvage RT; 73.4Gy for the other 50 pat. |
α/β ratio = 5Gy for late GU toxicity! 69.14Gy adjuvant RT; 77.1Gy salvage RT; 65.5Gy for the other 50 pat. |
Tomo-RT |
68 months median |
- |
41/247 (16.5%) ≥ III° GU in hypofraction arm; 72/929 (7.7%) in conventional arm |
- |
- |
- |
Kruse, T.J. [26] |
Retrospective for salvage RT |
Madison, Wisconsin |
108 patients |
65Gy/2.5Gy/26 fractions |
74.6Gy |
71.5Gy |
IMRT |
32.4 months median |
8 pat. (7%) II° and 1 pat. III° GU RTOG. |
16 pat. (15%) II° GU RTOG. |
15 pat. (14%) II GI RTOG. |
4 (4%) pat. II° GI RTOG. |
freedom from biochem. failure at 4 years 67% ± 5.3%. |
Ippolito, E. [24] |
Prospective phase I for dose-escalation, adjuvant RT |
Campobasso, Italy |
25 patients |
7 pat. 56.8Gy/2.27Gy/25 fractions; 6 pat. 59.7Gy/2.39Gy/25fractions; 6 pat. 61.25Gy/2.45Gy/25fractions; 6 pat. 62.5Gy/2.5Gy/25 fractions |
7 pat. 61.3Gy; 6 pat. 66.5Gy; 6 pat. 69.4Gy; 6 pat. 71.7Gy. |
7 pat. 59.9Gy; 6 pat. 64.4Gy; 6 pat. 66.8Gy; 6 pat. 68.8Gy. |
IMRT |
19 months median |
9/25 (36%) II° GU. |
- |
5/25 (20%) II° GI. |
- |
- |
Lee, W. [52] |
Retrospective for salvage RT |
Manchester |
37 patients |
50-52.5Gy/2.5-2.63Gy/20 fractions |
57.4-62.2Gy |
55-59.1Gy |
- |
30.6 months median |
0% II° GU. |
16 pat. I° GU, 0 pat. II° GU. |
0% II° GI. |
4 pat. I° GI, 1 pat. II° GI. |
3-year disease-free survival is 74%. |